256 related articles for article (PubMed ID: 28488185)
1. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
Khan N; Moskowitz AJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
[TBL] [Abstract][Full Text] [Related]
2. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
Ferhanoglu B; Ozbalak M
Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
[TBL] [Abstract][Full Text] [Related]
3. Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed and refractory Hodgkin Lymphoma.
von Tresckow B; Moskowitz CH
Semin Hematol; 2016 Jul; 53(3):180-5. PubMed ID: 27496309
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability.
Xavier FD; Farias DLC; Neto AEH; Ribeiro GN; Araujo MAS; Carneiro TX; Baiocchi OCCG
Oncotarget; 2023 Dec; 14():977-994. PubMed ID: 38085126
[TBL] [Abstract][Full Text] [Related]
7. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.
Colpo A; Hochberg E; Chen YB
Oncologist; 2012; 17(1):80-90. PubMed ID: 22210089
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
Voorhees TJ; Beaven AW
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050054
[TBL] [Abstract][Full Text] [Related]
9. Transplant strategies in relapsed/refractory Hodgkin lymphoma.
Shah GL; Moskowitz CH
Blood; 2018 Apr; 131(15):1689-1697. PubMed ID: 29500170
[TBL] [Abstract][Full Text] [Related]
10. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
Grover NS; Dittus C; Thakkar A; Beaven AW
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
[TBL] [Abstract][Full Text] [Related]
11. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
Jona A; Younes A
Blood Rev; 2010 Nov; 24(6):233-8. PubMed ID: 20828898
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin lymphoma: Focus on evolving treatment paradigms.
Roswarski JL; Longo DL
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101510. PubMed ID: 38092470
[TBL] [Abstract][Full Text] [Related]
13. Where does PD-1 blockade fit in HL therapy?
Herrera AF
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
[TBL] [Abstract][Full Text] [Related]
14. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.
Castellino SM; Giulino-Roth L; Harker-Murray P; Kahn JM; Forlenza C; Cho S; Hoppe B; Parsons SK; Kelly KM;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30580. PubMed ID: 37505794
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S; Ambinder RF
CA Cancer J Clin; 2018 Mar; 68(2):116-132. PubMed ID: 29194581
[TBL] [Abstract][Full Text] [Related]
16. Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens.
Mariotti J; Ricci F; Giordano L; Taurino D; Sarina B; De Philippis C; Mannina D; Carlo-Stella C; Bramanti S; Santoro A
Cells; 2024 Jan; 13(2):. PubMed ID: 38247809
[TBL] [Abstract][Full Text] [Related]
17. Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Diefenbach C; Advani R
Hematol Oncol Clin North Am; 2014 Feb; 28(1):105-22. PubMed ID: 24287071
[TBL] [Abstract][Full Text] [Related]
18. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies.
Vassilakopoulos TP; Chatzidimitriou C; Asimakopoulos JV; Arapaki M; Tzoras E; Angelopoulou MK; Konstantopoulos K
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31362369
[TBL] [Abstract][Full Text] [Related]
20. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.
Vassilakopoulos TP; Asimakopoulos JV; Konstantopoulos K; Angelopoulou MK
Ther Adv Hematol; 2020; 11():2040620720902911. PubMed ID: 32110285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
